Melissa Stolper, analyst at Decision Resources, is available to discuss the impact of Merck's withdrawal of Vioxx from the arthritis market.

Recently, Ms. Stolper completed in-depth analyses of the rheumatoid arthritis and osteoarthritis markets, including ten-year market forecasts based on the current and evolving therapeutic landscapes for RA and OA. These forecasts were completed prior to the withdrawal of Vioxx, but did factor in the impact of early warning signs pertaining to Vioxx's cardiovascular problems.

  Ms. Stolper can comment on:    * The Celebrex/Vioxx battle leading up to today's news    * Why Vioxx was withdrawn from the market and if it appears to be a class      problem or a Vioxx problem    * The potential problems Merck will have with their follow-up compound to      Vioxx    * The impact the withdrawal of Vioxx will have on the market  

To speak with Ms. Stolper, please contact Liz Marshall at Decision Resources at 781-296-2563 or

About Decision Resources

Decision Resources ( is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

PRNewswire/ -- Sept. 30

SOURCE: Decision Resources

Psoriasis Drug Market Will Grow Substantially, Reaching $3.3 Billion in 2013

View Now